Adcetris Substituting Vincristine in the OEPA/COPDac Regimen [Treatment Group 3 (TG3) of Euro-Net C1] With Low Dose Tailored-Field Radiation Therapy for Unfavorable Risk Pediatric Hodgkin Lymphoma
Phase of Trial: Phase II
Latest Information Update: 02 Sep 2017
At a glance
- Drugs Brentuximab vedotin (Primary) ; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Filgrastim; Prednisolone
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 23 Apr 2015 Planned End Date changed from 1 Aug 2022 to 1 Apr 2025 as reported by ClinicalTrials.gov record.
- 23 Apr 2015 Planned primary completion date changed from 1 Oct 2020 to 1 Aug 2021 as reported by ClinicalTrials.gov record.
- 23 Apr 2015 Planned number of patients changed from 134 to 77 as reported by ClinicalTrials.gov record.